[go: up one dir, main page]

Song et al., 2013 - Google Patents

Synthesis and characterization of Pt (IV) fluorescein conjugates to investigate Pt (IV) intracellular transformations

Song et al., 2013

View PDF
Document ID
756659576469688843
Author
Song Y
Suntharalingam K
Yeung J
Royzen M
Lippard S
Publication year
Publication venue
Bioconjugate chemistry

External Links

Snippet

Pt (IV) anticancer compounds typically operate as prodrugs that are reduced in the hypoxic environment of cancer cells, losing two axial ligands in the process to generate active Pt (II) species. Here we report the synthesis of two fluorescent Pt (IV) prodrugs of cisplatin in order …
Continue reading at pmc.ncbi.nlm.nih.gov (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/30—Copper compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48007—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the pharmacologically- or therapeutically-active agent being covalently bound or complexed to a modifying agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic System
    • C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic System compounds of the platinum group
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells

Similar Documents

Publication Publication Date Title
Song et al. Synthesis and characterization of Pt (IV) fluorescein conjugates to investigate Pt (IV) intracellular transformations
Lenis-Rojas et al. RuII (p-cymene) compounds as effective and selective anticancer candidates with no toxicity in vivo
Riccardi et al. Anticancer ruthenium (III) complexes and Ru (III)-containing nanoformulations: An update on the mechanism of action and biological activity
Wang et al. Dual functions of cyclometalated iridium (III) complexes: anti-metastasis and lysosome-damaged photodynamic therapy
Zobi et al. Live-fibroblast IR imaging of a cytoprotective photoCORM activated with visible light
Zheng et al. Pt (IV) prodrugs designed to bind non-covalently to human serum albumin for drug delivery
Klein et al. Platinum drug distribution in cancer cells and tumors
Sun et al. Mitochondria-localized fluorescent BODIPY-platinum conjugate
You et al. Phosphorescent sensor for biological mobile zinc
Villarreal et al. Chiral platinum (II) complexes featuring phosphine and chloroquine ligands as cytotoxic and monofunctional DNA-binding agents
Benedetti et al. Effects of noncovalent platinum drug–protein interactions on drug efficacy: use of fluorescent conjugates as probes for drug metabolism
Jin et al. Targeting energy metabolism by a platinum (IV) prodrug as an alternative pathway for cancer suppression
Wirth et al. Azide vs alkyne functionalization in Pt (II) complexes for post-treatment click modification: solid-state structure, fluorescent labeling, and cellular fate
Heffern et al. Tuning cobalt (III) Schiff base complexes as activated protein inhibitors
Chen et al. Wide-acidity-range pH fluorescence probes for evaluation of acidification in mitochondria and digestive tract mucosa
Panchangam et al. Antitumor effects of Ir (III)-2 H-indazole complexes for triple negative breast cancer
Sarkar et al. Mixed-ligand cobalt (III) complexes of a naturally occurring coumarin and phenanthroline bases as mitochondria-targeted dual-purpose photochemotherapeutics
Liu et al. DNA binding and photocleavage properties, cellular uptake and localization, and in-vitro cytotoxicity of dinuclear ruthenium (II) complexes with varying lengths in bridging alkyl linkers
White et al. Multifunctional Pt (II) reagents: covalent modifications of Pt complexes enable diverse structural variation and in-cell detection
Mitra et al. 2-(Phenylazo) pyridineplatinum (II) catecholates showing photocytotoxicity, nuclear uptake, and glutathione-triggered ligand release
Mandal et al. Brief research on the biophysical study and anticancer behavior of Pt (II) complexes: their DNA/BSA binding, molecular docking, and cytotoxic property
Muhammad et al. Multiaction platinum (IV) prodrug containing thymidylate synthase inhibitor and metabolic modifier against triple-negative breast cancer
Mertens et al. Synthetic control of mitochondrial dynamics: developing three-coordinate au (I) probes for perturbation of mitochondria structure and function
Gupta et al. Multifunctional iridium (III)–platinum (IV) conjugates as potent anticancer theranostic agents
Ribeiro et al. Ruthenium (II) phosphine/mercapto complexes: their in vitro cytotoxicity evaluation and actions as inhibitors of topoisomerase and proteasome acting as possible triggers of cell death induction